The AACR and Stand Up To Cancer

The American Association for Cancer Research (AACR) is proud to be the Scientific Partner of Stand Up To Cancer (SU2C), the highly successful fundraising and cancer research support division of the Entertainment Industry Foundation, a major charity based in Los Angeles. 

During SU2C's latest nationwide fundraising telecast, actor and real-life physician Ken Jeong, MD (pictured here with actress,SU2C Telecast_AACR Logo_for_website.png journalist and brain cancer survivor Maria Menounos), was one of the hosts.  He described the role of the AACR:  "This great organization brings the scientists together and makes sure the funding goes to the best research that will save lives now.  With dedication and brilliance, the American Association for Cancer Research makes it all work."

SU2C leverages the resources of the entertainment industry to increase awareness of the urgent need for cancer research and raises funds to support unique research initiatives, with a majority of its programs carried out through a collaborative model involving top scientists at leading institutions. To date, more than $603 million has been pledged in support of SU2C’s innovative cancer research programs. 

The scientific program of Dream Teams, Research Teams, Innovative Research Grants, and Phillip A. Sharp Innovation in Collaboration Awards is led by a blue-ribbon Scientific Advisory Committee (SAC) composed of highly accomplished laboratory researchers, physician-scientists, and advocates, and chaired by Nobel Laureate Phillip A. Sharp, PhD, institute professor at the Massachusetts Institute of Technology (MIT) in Boston and its David H. Koch Institute for Integrative Cancer Research. Serving as vice-chairs are:

  • Nobel Laureate Elizabeth H. Blackburn, PhD, the Morris Herzstein professor emerita at the University of California San Francisco and president emerita of the Salk Institute for Biological Studies; 
  • Raymond N. DuBois, MD, PhD, professor and dean of the College of Medicine at the Medical University of South Carolina; 
  • Lee J. Helman, MD, director of the cancer and blood diseases research program at The Saban Research Institute of Children's Hospital Los Angeles;
  • Arnold J. Levine, PhD, professor emeritus at the Institute for Advanced Study in Princeton, New Jersey; and  
  • William G. Nelson, MD, PhD, director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore.  

Working with the SAC and a specific advisory committee for each project, the AACR manages all phases of the grant cycle from the funding opportunity announcement to the rigorous and competitive review process to identify the best research proposals to recommend for funding. After each grant is launched, AACR manages scientific oversight and research progress review, ensuring that the projects remain on schedule and meet their projected milestones.

To date, the AACR has managed the selection and oversight of:

  • 26 Dream Teams;
  • 5 Research Teams;
  • 13 SU2C Catalyst® Research Teams;
  • 7 teams in the Pancreatic Cancer Collective;
  • 46 Innovative Research Grants to individual young investigators; and
  • 28 Phillip A. Sharp Awards for "innovation in collaboration" among teams and researchers.

Altogether, SU2C has involved more than 1,600 researchers representing more than 180 leading institutions around the world. SU2C researchers have been involved in more than 180 planned, launched, or completed clinical trials, and more than 12,000 patients have participated in SU2C-related trials. Scientists have published more than 1,100 scientific papers in peer-reviewed journals reporting on SU2C-associated research.